PMI Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 2030617 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $217,000 | $2.95M | $1.15M | $1.01M | $1.19M | $2.13M | $620,000 | $836,000 |
| Cost of revenue | $122,000 | $2.34M | $875,000 | $598,000 | $1.32M | $2.26M | $978,000 | $700,000 |
| Gross profit | $95,000 | $616,000 | $275,000 | $411,000 | -$130,000 | -$127,000 | -$358,000 | $136,000 |
| R&D expense | $321,000 | $1.37M | $1.90M | $547,000 | $951,000 | $743,000 | $808,000 | $789,000 |
| SG&A expense | $1.88M | $3.87M | $2.89M | $2.87M | $2.41M | $2.65M | $2.08M | $2.92M |
| Operating income | -$2.10M | -$4.63M | -$4.51M | -$3.00M | -$3.49M | -$3.52M | -$3.25M | -$3.57M |
| Interest expense | — | — | — | — | — | $2.43M | — | — |
| Pretax income | -$2.22M | -$5.65M | -$7.62M | -$4.29M | -$10.43M | -$6.72M | -$5.53M | -$8.85M |
| Income tax | $0 | $7,000 | $0 | $4,000 | $0 | $0 | $31,000 | -$15,000 |
| Net income | -$2.22M | -$5.66M | -$7.62M | -$4.29M | -$10.43M | -$6.72M | -$5.56M | -$8.84M |
| EBITDA | -$2.06M | -$4.58M | -$4.46M | -$2.96M | -$3.45M | -$3.08M | -$3.20M | -$3.53M |
| EPS (basic) | -0.95 | -3.05 | -0.10 | — | -9.57 | -42.39 | -0.80 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Dividends declared per share | — | — | — | — | 0.00 | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $67,000 | $38,000 | $121,000 | $7.45M | $2.81M | $410,000 | — | $96,000 |
| Receivables | — | — | — | — | — | $1.30M | — | $513,000 |
| Inventory | $6.38M | $5.97M | $7.45M | $7.30M | $6.55M | $7.00M | — | $8.12M |
| Current assets | $7.63M | $7.59M | $9.51M | $20.73M | $11.59M | $9.64M | — | $9.79M |
| PP&E, net | $140,000 | $162,000 | $184,000 | $183,000 | $169,000 | $188,000 | — | $227,000 |
| Goodwill | $615,000 | $615,000 | $615,000 | $615,000 | $615,000 | $615,000 | — | $615,000 |
| Intangibles | $443,000 | $465,000 | $487,000 | $509,000 | $531,000 | $553,000 | — | $596,000 |
| Total assets | $9.06M | $9.17M | $11.22M | $22.55M | $13.52M | $11.70M | — | $12.11M |
| Current liabilities | $7.73M | $7.45M | $12.66M | $18.70M | $5.37M | $45.64M | — | $35.33M |
| Total liabilities | $7.73M | $7.45M | $12.67M | $18.76M | $5.55M | $45.93M | — | $35.84M |
| Shareholders' equity | $1.33M | $1.72M | -$1.45M | $3.79M | $7.97M | -$54.49M | -$48.92M | -$44.00M |
| Shares outstanding | 2.46M | 2.06M | 75.26M | 1.47M | 73.70M | 9.29M | — | 7.94M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.00M | -$1.35M | -$3.80M | -$4.38M | -$6.51M | -$2.54M | -$2.24M | -$3.15M |
| Capital expenditure | $0 | $0 | $26,000 | — | $0 | $0 | $0 | — |
| Free cash flow | -$2.00M | -$1.35M | -$3.83M | — | -$6.51M | -$2.54M | -$2.24M | — |
| Investing cash flow | $0 | $0 | -$26,000 | — | $0 | $0 | $0 | $0 |
| Financing cash flow | $2.03M | $1.25M | -$7.52M | $13.02M | $8.95M | $2.28M | $2.83M | $3.23M |
| Depreciation & amortization | $44,000 | $45,000 | $46,000 | $40,000 | $41,000 | $442,136 | $42,000 | $42,000 |
| Stock-based compensation | $93,000 | $1.38M | $165,000 | $226,000 | $204,000 | $183,000 | $141,000 | $226,000 |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.